Vitiligo Prevalence and Patient Burden

Video

John E. Harris, MD, PhD, reviews factors that shape prevalence of vitiligo and also explores the impact of vitiligo on patient quality of life.

Related Videos
Oral Upadacitinib Significantly Reduces Facial, Total Nonsegmental Vitiligo Through 52 Weeks
Amit Pandya, MD: The Discovery of Oral Tranexamic Acid for Melasma
Amit Pandya, MD: Ruxolitinib Cream in Real-World Vitiligo Patients of Color
Related Content
Vitiligo Patients Face Higher All-Cause, Vitiligo-Related Costs Compared to Those Without

Vitiligo Patients Face Higher All-Cause, Vitiligo-Related Costs Compared to Those Without

February 1st 2024
Article
The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes

The Latest Data for Ruxolitinib Cream in Vitiligo: Finding Context from the Outcomes

May 10th 2023
Podcast
Active Vitiligo Considered a Risk Factor for Vitiligo Progression Following COVID-19 Vaccination

Active Vitiligo Considered a Risk Factor for Vitiligo Progression Following COVID-19 Vaccination

January 9th 2024
Article
What Ruxolitinib Cream Meant For Dermatology in 2022

What Ruxolitinib Cream Meant For Dermatology in 2022

December 20th 2022
Podcast
Greater Vitiligo Risk Seen Among Transplant Recipients, Patients with Comorbid Graft-vs-Host Disease

Greater Vitiligo Risk Seen Among Transplant Recipients, Patients with Comorbid Graft-vs-Host Disease

December 15th 2023
Article
Oral Povorcitinib for Extensive Nonsegmental Vitiligo Yields Positive Results in Phase 2b Trial

Oral Povorcitinib for Extensive Nonsegmental Vitiligo Yields Positive Results in Phase 2b Trial

October 11th 2023
Article
© 2024 MJH Life Sciences

All rights reserved.